cis-1,4-Dimethoxycyclohexan | 28046-68-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-1,4-Dimethoxycyclohexan
• CAS: 28046-68-6
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: SVHAWXAAVLMPLW-OCAPTIKFSA-N

物化性质

• 沸点：
  173.9±8.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)

文献信息

• [EN] BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF<br/>[FR] COMPOSÉS PONTÉS EN TANT QU'INHIBITEUR ET DÉGRADEUR DE KRAS G12D ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2022148422A1

  公开（公告）日：2022-07-14

  Provided herein are Bridged Compounds having the following structures: (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, R3c, R3d, R4, R5, R6, R7, R8, m1, m2, m3, n2, n3, n4, q, X1, X2, Y1, Y2, L1and ring A are as defined herein, compositions comprising an effective amount of a Bridged Compound, and methods for treating or preventing various diseases, e.g., pancreatic cancer, or a condition treatable or preventable by inhibition of the function of KRAS protein. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of the function of KRAS protein with G12D mutation. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of a RAS/MAPK pathway.

  本文提供了具有以下结构的桥接化合物：（I），其中R1a，R1b，R1c，R1d，R2a，R2b，R2c，R2d，R3a，R3b，R3c，R3d，R4，R5，R6，R7，R8，m1，m2，m3，n2，n3，n4，q，X1，X2，Y1，Y2，L1和环A的定义如本文所述，包含有效量的桥接化合物的组合物，以及用于治疗或预防各种疾病的方法，例如胰腺癌或可通过抑制KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制具有G12D突变的KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制RAS / MAPK途径来治疗或预防的疾病。
• Heterocyclic compound serving as FGFR4 inhibitor
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US11352353B2

  公开（公告）日：2022-06-07

  A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

  一种杂环化合物，该化合物为FGFR4的抑制剂。具体地，所述化合物如以下的式(I)所示，包括其存在的异构体(包括对映体或非对映体)，或者所述化合物的药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。其定义如权利要求所述。所述化合物具有FGFR4抑制活性，可以用于预防或治疗与FGFR4活性或表达相关的疾病，同时也可用于与其它药物合用，用于治疗多种相关疾病。
• SUBSTITUTED AZINES AS PESTICIDES
  申请人：Novartis Tiergesundheit AG

  公开号：EP2882733B1

  公开（公告）日：2017-04-26
• HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US20200199120A1

  公开（公告）日：2020-06-25

  A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.